

UPDATE ON MILESTONES IN INVION'S 4 DRUG DEVELOPMENT PROGRAMS

Brisbane, Australia and Delaware, United States, 2 July 2015: Australian respiratory and inflammation technology company Invion Limited (ASX: IVX) is pleased to provide the following update to investors on milestones outlined in March 2015 across its four development programs:

1H 2015

Oral INV102 (nadolol)

- ✓ Blind-broken interim data from phase II smoking cessation trial
- ✓ Completion of enrolment in phase II smoking cessation trial
- ✓ Completion of dosing in phase II smoking cessation trial

Inhaled INV102 (nadolol)

- ✓ Pre-IND status for inhaled nadolol as a potential therapy for asthma, COPD & cystic fibrosis
- ✓ Manufacture of toxicology and clinical supplies
- ✓ Commencement of toxicology studies

Milestones anticipated by mid-Q3 2015

- Data from phase II oral INV102 (nadolol) study in patients undergoing smoking cessation (no change)
- Data from phase II clinical trial of INV103 (ala-Cpn10) in lupus patients (revised from 1H15 further to enrolment delay in the final cohort of patients)
- Selection of formulation and device for inhaled INV104 (zafirlukast) (revised from 1H15)

Milestones anticipated 2H 2015

- Completion of enrolment of NIH-funded phase II study of INV102 (nadolol) in asthma patients (no change)

About Invion Limited

Invion is a life sciences company focussed on the development of treatments for major opportunities in respiratory disease and autoimmune disease. The Group has three drug assets in development, and three phase II clinical trials, regulated by the Food & Drug Administration (FDA), currently underway in the United States. INV102 (nadolol) a beta blocker (beta adrenergic inverse agonist) currently used to treat high blood pressure and migraine, is being repurposed to treat chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a modified, naturally occurring human protein which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesised to maintain and restore immune homeostasis. Invion is an ASX listed company (ASX:IVX), with its clinical headquarters in Delaware, USA. **FOR MORE INFORMATION CONTACT** Managing Director and CEO: Dr Greg Collier. P: 07 3295 0500 greg.collier@inviongroup.com